1. Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery 
Brian T. Bateman, MD, Jeremy A. Rassen, ScD, Sebastian Schneeweiss, MD, ScD, Katsiaryna Bykov, PharmD, MS, Jessica Myers Franklin, PhD, Joshua J. Gagne, PharmD, ScD, Jennifer M. Polinski, ScD, MPH, Jun Liu, MD, MPH, Alexander Kulik, MD, MPH, Michael A. Fischer, MD, MS, Niteesh K. Choudhry, MD, PhD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 146, Issue 2, Pages (August 2013)
DOI: /j.jtcvs
Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
Patient flow chart. CABG, Coronary artery bypass graft; CDI, Clostridium difficile infection.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

3. Figure 2
Proportion of cephalosporin-exposed patients undergoing coronary artery bypass grafting who received adjuvant vancomycin, by year.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions